Do most people keep weight off after stopping GLP-1 drugs?

What did @mayacox00 actually say?

Here's the uncomfortable truth: the transcript from this video is not a coherent health claim. What was captured word-for-word is a string of filler sounds and song lyrics, something like "Blam Blam, baby, baby" and "Straight runner times you." There is no verifiable spoken medical claim in the actual audio.

The caption, however, does make specific claims worth examining. It states that researchers tracked "8,000 real people" and found that "most actually kept their weight steady for over 1 year" after stopping GLP-1 medications, and that "27% switched medications" as a key differentiator. Since the caption is the content a viewer actually reads, those numbers deserve scrutiny.

Does the science back this up?

Sort of, but the framing is doing a lot of heavy lifting here. The best available data on GLP-1 discontinuation paints a more complicated picture than "most people stayed steady."

The STEP 4 trial (Rubino et al., 2021, JAMA) is the most cited discontinuation study. After stopping semaglutide, participants regained about two-thirds of their lost weight within 12 months. A separate real-world analysis from Wilding et al. (2022, Diabetes, Obesity and Metabolism) found similar patterns in observational data. Neither study describes a majority of people "keeping weight steady."

The 8,000-person figure and the 27% medication-switching stat are not traceable to any single published peer-reviewed study in the major GLP-1 literature as of mid-2024. That does not mean they are fabricated, but unverifiable numbers in a health caption are a red flag, not a green light.

What did they get wrong (or right)?

The caption gets credit for one thing: pushing back on the idea that weight returns "instantly." That is an overstatement that circulates in GLP-1 discourse, and the science does show that regain is gradual, not overnight. Rubino et al. (2021) tracked regain over 52 weeks, not 52 hours. That nuance is real and worth saying.

Where the caption goes wrong is the implicit suggestion that weight maintenance after stopping is common or expected. The clinical data consistently shows it is the exception, not the rule. Appetite-regulating hormones and hypothalamic signaling that GLP-1 medications modulate tend to revert toward baseline after discontinuation, per Sumithran et al. (2011, New England Journal of Medicine), who showed hunger hormones rebounding even a year after weight loss. The body does not simply stay in a new set point.

The "27% switched medications" framing is also doing quiet work. It implies switching is a clean solution, without noting that access, cost, and tolerability make switching complicated for most patients.

What should you actually know?

If you are thinking about stopping a GLP-1 medication, the realistic picture is this: weight regain is common, gradual, and biological, not a personal failure. Studies suggest most people regain a significant portion of lost weight within one to two years of stopping, though there is genuine individual variation that researchers are still trying to explain.

Some people do sustain weight loss after discontinuation, and behavioral factors like physical activity patterns and dietary habits appear to matter, though the mechanisms are not fully understood (Blundell et al., 2020, International Journal of Obesity). Switching to a different GLP-1 or dual-agonist like tirzepatide is a real clinical option some providers consider, but it is not a universal solution, and it requires a provider conversation, not a TikTok caption.

The bottom line: do not stop or switch weight loss medication based on social media statistics that cannot be traced to a study. Talk to a prescribing clinician who knows your history.